Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Roberts Joseph 2. Date of Event Requiring Statement (Month/Day/Year) 12/12/2025 3. Issuer Name and Ticker or Trading Symbol Arcturus Therapeutics Holdings Inc. [ARCT] (Last) (First) (Middle) C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10285 SCIENCE CENTER DRIVE 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Controller 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SAN DIEGO, CA 92121 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 2,001 D Common Stock 200 I Spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	08/24/2028	Common Stock	5,000	$8	D
Stock Option (Right to Buy)	(2)	02/18/2030	Common Stock	5,000	$14.12	D
Stock Option (Right to Buy)	(3)	12/18/2030	Common Stock	2,808	$99.29	D
Stock Option (Right to Buy)	(4)	12/18/2030	Common Stock	6,492	$99.29	D
Stock Option (Right to Buy)	(5)	12/10/2031	Common Stock	7,000	$34.57	D
Stock Option (Right to Buy)	(6)	12/09/2032	Common Stock	7,000	$16.92	D
Stock Option (Right to Buy)	(7)	12/15/2033	Common Stock	7,500	$28.88	D
Stock Option (Right to Buy)	(8)	02/22/2034	Common Stock	1,000	$37.44	D
Stock Option (Right to Buy)	(9)	12/16/2034	Common Stock	9,000	$16.24	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Roberts Joseph C/O ARCTURUS THERAPEUTICS HOLDINGS INC. 10285 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121			Controller

Signatures

/s/ Grant Levine, attorney-in-fact		12/19/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on August 24, 2018.
(2)	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on February 18, 2020.
(3)	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 18, 2020.
(4)	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 18, 2020.
(5)	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 10, 2021.
(6)	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 9, 2022.
(7)	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 15, 2023.
(8)	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on February 22, 2024.
(9)	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 16, 2024.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.